WO2011156900A3 - Composés, compositions et procédés pour traiter la sclérose en plaques - Google Patents

Composés, compositions et procédés pour traiter la sclérose en plaques Download PDF

Info

Publication number
WO2011156900A3
WO2011156900A3 PCT/CA2011/000694 CA2011000694W WO2011156900A3 WO 2011156900 A3 WO2011156900 A3 WO 2011156900A3 CA 2011000694 W CA2011000694 W CA 2011000694W WO 2011156900 A3 WO2011156900 A3 WO 2011156900A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compounds
multiple sclerosis
compositions
treatment
Prior art date
Application number
PCT/CA2011/000694
Other languages
English (en)
Other versions
WO2011156900A2 (fr
Inventor
Antonio Cruz
Original Assignee
Waratah Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Waratah Pharmaceuticals Inc. filed Critical Waratah Pharmaceuticals Inc.
Publication of WO2011156900A2 publication Critical patent/WO2011156900A2/fr
Publication of WO2011156900A3 publication Critical patent/WO2011156900A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des composés, compositions, formes galéniques et des méthodes faisant intervenir de l'hydrochlorure de 6-phényl-4-pyridin-4-yl-3-(4-pyrimidin-2-yl-pipérazin-1-yl)-pyridazine ou un sel pharmaceutiquement acceptable correspondant, ainsi que des méthodes pour traiter une sclérose en plaques chez un sujet au moyen de ceux-ci.
PCT/CA2011/000694 2010-06-17 2011-06-16 Composés, compositions et procédés pour traiter la sclérose en plaques WO2011156900A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35578910P 2010-06-17 2010-06-17
US61/355,789 2010-06-17

Publications (2)

Publication Number Publication Date
WO2011156900A2 WO2011156900A2 (fr) 2011-12-22
WO2011156900A3 true WO2011156900A3 (fr) 2012-02-09

Family

ID=45348589

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2011/000694 WO2011156900A2 (fr) 2010-06-17 2011-06-16 Composés, compositions et procédés pour traiter la sclérose en plaques

Country Status (1)

Country Link
WO (1) WO2011156900A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3823623A1 (fr) * 2018-07-20 2021-05-26 Merck Patent GmbH Composé amino-pyrimidine substitué destiné à être utilisé pour le traitement et la prévention de la sclérose en plaques
WO2023163951A1 (fr) * 2022-02-23 2023-08-31 Immunochem Therapeutics, Llc Traitement de l'hémorragie intracrânienne

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007127475A2 (fr) * 2006-04-28 2007-11-08 Northwestern University Compositions et traitements contre des maladies démyélinisantes et des troubles de type douleur

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007127475A2 (fr) * 2006-04-28 2007-11-08 Northwestern University Compositions et traitements contre des maladies démyélinisantes et des troubles de type douleur

Also Published As

Publication number Publication date
WO2011156900A2 (fr) 2011-12-22

Similar Documents

Publication Publication Date Title
SA515360469B1 (ar) مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها
WO2008148074A3 (fr) Inhibiteurs de mtor et methodes de traitement mettant en œuvre ces inhibiteurs
WO2012062925A3 (fr) Composés et procédés de traitement de la douleur
UA108087C2 (uk) Тверді форми n-(4-(7-азабіцикло[2.2.1]гептан-7-іл)-2-(трифторметил)феніл)-4-оксо-5-(трифторметил)-1,4-дигідрохінолін-3-карбоксаміду
WO2012024620A3 (fr) Inhibiteurs de l'autotaxine et leurs utilisations
WO2012046030A3 (fr) Inhibiteurs de phosphodiestérase
WO2012002688A3 (fr) Procédés de traitement du syndrome des jambes sans repos
PH12014501273A1 (en) Intranasal dexmedetomidine compositions and methods of use thereof
EP2883875A4 (fr) Dérivé de n2,n4-bis(4-(pipérazine-1-yl)phényl)pirimidine-2,4-diamine ou sel pharmaceutiquement acceptable de celui-ci, et composition contenant celle-ci en tant que substance active pour prévenir ou traiter un cancer
IN2014KN00948A (fr)
WO2011127333A3 (fr) Composés pour le traitement d'une maladie, pour l'administration, et pour des compositions pharmaceutiques
WO2011055944A3 (fr) Procédés pour traiter un syndrome de fibromyalgie
WO2012002687A3 (fr) Procédés de traitement du trouble bipolaire
WO2011113060A3 (fr) Composés antiviraux et procédés d'utilisation de ceux-ci
WO2012158672A3 (fr) Composés utilisés dans le traitement de la mucosite
MX2014008020A (es) Compuestos de fenil carbamato para uso en la prevencion o tratamiento de epilepsia.
EA201691759A1 (ru) Композиции и способы лечения легочной гипертензии
GEP20186880B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
ZA201401678B (en) Novel distributed 3,4-diamino-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases
GEP201706656B (en) 2-thiopyrimidinones
WO2013098416A3 (fr) Composes anti-douleur
WO2012118308A3 (fr) Composition contenant un dérivé de pyrazole destinée à prévenir et à traiter les maladies cardiovasculaires
WO2012017321A3 (fr) Traitement de la dyslipidémie
JO3145B1 (ar) مركبات مفيدة لتثبيط chk1
EP3406242B8 (fr) Antagoniste du tlr4 destiné à être utilisé dans le traitement de l'augmentation des taux plasmatiques d'ammoniac

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11794985

Country of ref document: EP

Kind code of ref document: A2